Disease · HP_0000010
Recurrent urinary tract infections
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Recurrent urinary tract infections. Diseases, record HP_0000010. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000010
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Recurrent urinary tract infections
- Open Targets ID
- HP_0000010
- Other names
- Frequent urinary tract infections, Recurrent UTIs, Repeated bladder infections, Repeated urinary tract infections, Urinary tract infections, Urinary tract infections, recurrent
- Highest stage of its drugs
- Phase 2, for 5 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CEFIXIME | CHEMBL1541 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEPHALEXIN | CHEMBL1200544 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CO-TRIMOXAZOLE | CHEMBL58061 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRIMETHOPRIM | CHEMBL22 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/2099 |
Source Drugs and targets
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01595529 | The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" | Phase 2 | 717 | 2020-07-13 | Urinary Tract Infection | CEFIXIME, CEPHALEXIN, TRIMETHOPRIM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01923298 | Estradiol Levels in Patients Treated With Estring | Phase 2 | 14 | 2022-02-04 | Estrogen Levels Among Breast Cancer Patients | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. | 11 of 328 | 29 of 336 | 664 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. | 30 of 328 | 41 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. | 2 of 328 | 14 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: deaths from any cause | 0 of 328 | 0 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. | 6 of 328 | 41 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: serious adverse events | 2 of 328 | 4 of 336 | 664 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. | 12 of 326 | 13 of 322 | 648 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population. | 2 of 308 | 9 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population. | 6 of 308 | 35 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population | 29 of 308 | 33 of 314 | 622 | NCT01595529 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000010
GET https://conductscience.org/api/diseases/v1/HP_0000010/drugs